Abstract
The tumor cell growth inhibitory activities (log 1 / GI50) of 166 anticancer agents studied at the National Cancer Institute (NCI) in vitro anticancer screening program have allowed us to analyze the relative importance of physicochemical parameters in influencing the inhibitory activities. Increased molecular weight, as measured by the logarithm of molecular weight (log MW), is found to be an important contributor to the tumor cell growth inhibitory activities. The tumor cell growth inhibitory activities in different subpanels of the tumor cells are highly inter-correlated with each other. A simple binary quantitative structure-activity relationship (QSAR) model was derived from the 166 anticancer drugs, based on the tumor cell growth inhibitory activities transformed into a binary (active or inactive) data format. The model obtained can be tested with additional new data, and may be useful to identify active compounds from a large compound library to be included in high throughput screening.
Keywords: anticancer agents, binary qsar, molecular weight, qsar, tumor cell growth inhibitory activity
Current Pharmaceutical Design
Title: Anticancer Agents: Tumor Cell Growth Inhibitory Activity and Binary QSAR Analysis
Volume: 10 Issue: 12
Author(s): Steven S. Ren and Eric J. Lien
Affiliation:
Keywords: anticancer agents, binary qsar, molecular weight, qsar, tumor cell growth inhibitory activity
Abstract: The tumor cell growth inhibitory activities (log 1 / GI50) of 166 anticancer agents studied at the National Cancer Institute (NCI) in vitro anticancer screening program have allowed us to analyze the relative importance of physicochemical parameters in influencing the inhibitory activities. Increased molecular weight, as measured by the logarithm of molecular weight (log MW), is found to be an important contributor to the tumor cell growth inhibitory activities. The tumor cell growth inhibitory activities in different subpanels of the tumor cells are highly inter-correlated with each other. A simple binary quantitative structure-activity relationship (QSAR) model was derived from the 166 anticancer drugs, based on the tumor cell growth inhibitory activities transformed into a binary (active or inactive) data format. The model obtained can be tested with additional new data, and may be useful to identify active compounds from a large compound library to be included in high throughput screening.
Export Options
About this article
Cite this article as:
Ren S. Steven and Lien J. Eric, Anticancer Agents: Tumor Cell Growth Inhibitory Activity and Binary QSAR Analysis, Current Pharmaceutical Design 2004; 10 (12) . https://dx.doi.org/10.2174/1381612043384925
DOI https://dx.doi.org/10.2174/1381612043384925 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Insights into Targeting NEMO for Pharmacological Regulation
Current Drug Targets Role of TGF- β in the Tumor Stroma
Current Cancer Drug Targets Extrahepatic Targets and Cellular Reactivity of Drug Metabolites
Current Medicinal Chemistry In vitro Evaluation of Biological Effects of Metallic Compounds with Quinolines
Current Enzyme Inhibition Diet-Derived Phytochemicals: From Cancer Chemoprevention to Cardio-Oncological Prevention
Current Drug Targets Natural Products to Improve Quality of Life Targeting for Colon Drug Delivery
Current Drug Delivery Chemoresistance in High-Grade Gliomas: Relevance of Adenosine Signalling in Stem-Like Cells of Glioblastoma Multiforme
Current Drug Targets An Overview on the Pharmacokinetics of Quantum Dots
Current Drug Metabolism Mitochondria-Mediated Oxidative Stress: Old Target for New Drugs
Current Medicinal Chemistry Targeting the Multidrug ABCG2 Transporter with Flavonoidic Inhibitors: In Vitro Optimization and In Vivo Validation
Current Medicinal Chemistry Edelfosine in Membrane Environment - the Langmuir Monolayer Studies
Anti-Cancer Agents in Medicinal Chemistry Posttranslational Regulation of O6-Methylguanine-DNA Methyltransferase (MGMT) and New Opportunities for Treatment of Brain Cancers
Mini-Reviews in Medicinal Chemistry Angiotensin II Receptor Blocker: Possibility of Antitumor Agent for Prostate Cancer
Mini-Reviews in Medicinal Chemistry Amyloid-β Peptides, Alzheimer's Disease and the Blood-brain Barrier
Current Alzheimer Research Implications of the Dominant Role of Transporters in Drug Uptake by Cells
Current Topics in Medicinal Chemistry Preclinical and Clinical Efficacy of the Bisphosphonate Ibandronate in Cancer Treatment
Current Clinical Pharmacology Phosphorylation Processes Controlling Aromatase Activity in Br east Cancer: An Update
Mini-Reviews in Medicinal Chemistry Cigarette Smoke Decreases Salivary 18 kDa Translocator Protein Binding Affinity – in Association with Oxidative Stress
Current Medicinal Chemistry IgG4-Related Disease (IgG4+MOLPS) – Diagnostic Criteria and Diagnostic Problems
Current Immunology Reviews (Discontinued) Gold Nanoparticles - Synthesis and Applications in Cancer Management
Recent Patents on Materials Science